US Drug Recall Register

FDA Drug Recalls

2,277 recalls · Class II, newest first

Class II · Moderate risk Ongoing

Sunitinib Malate Capsules

Reason Labeling: Label Mix-Up

AvKARE NDC 42291-901-28 D-0103-2025
Class II · Moderate risk Ongoing

OneLAX Docusate Sodium Liquid

Reason CGMP Deviations

Akron Pharma, Inc. NDC 71399-0039-06 D-0025-2025
Class II · Moderate risk Ongoing

Cinacalcet Tablets

Reason CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.

Accord Healthcare, INC. D-0032-2025
Class II · Moderate risk Ongoing

Cinacalcet Tablets

Reason CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.

Accord Healthcare, INC. D-0031-2025
Class II · Moderate risk Ongoing

Cinacalcet Tablets 30 mg

Reason CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.

Accord Healthcare, INC. D-0030-2025
Class II · Moderate risk Ongoing

Cinacalcet Tablets

Reason CGMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit

Dr. Reddy's Laboratories, Inc. NDC 43598-369-30 D-0028-2025
Class II · Moderate risk Ongoing

Cinacalcet Tablets

Reason CGMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit

Dr. Reddy's Laboratories, Inc. NDC 43598-368-30 D-0027-2025
Class II · Moderate risk Ongoing

Cinacalcet Tablets

Reason CGMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit

Dr. Reddy's Laboratories, Inc. NDC 43598-367-30 D-0026-2025
Class II · Moderate risk Ongoing

Liceout

Reason CGMP violations.

Neogen Corporation D-0074-2025
Class II · Moderate risk Ongoing

Liceout

Reason CGMP violations.

Neogen Corporation D-0073-2025
Class II · Moderate risk Ongoing

AK Forte Ortiga y Omega 3 Cont. Neto 100 Tabletas

Reason Marketed without an Approved NDA/ANDA: FDA analysis found the product to be tainted with undeclared diclofenac and acetaminophen.

C & A Naturistics D-0024-2025
Class II · Moderate risk Ongoing

Dapsone Gel 7.5%

Reason Crystallization

Viona Pharmaceuticals INC NDC 72578-094-02 D-0011-2025
Class II · Moderate risk Ongoing

Ryaltris

Reason Defective Delivery System: The dip tube is clogged causing the spray not to work.

Glenmark Pharmaceuticals Inc., USA NDC 59467-700-27 D-0006-2025
Class II · Moderate risk Ongoing

Pluvicto

Reason CGMP deviations

Advanced Accelerator Applications USA, Inc. NDC 69488-0010-61 D-0007-2025
Class II · Moderate risk Ongoing

EnviroClean Hand Sanitizer Gel

Reason CGMP deviations

EnviroServe Chemicals Inc. NDC 76563-3010-1 D-0667-2024
Class II · Moderate risk Ongoing

Refresh LACRI-LUBE

Reason Lack of Assurance of Sterility: The impacted lots may contain a breach in the tube seal.

AbbVie Inc. D-0665-2024
Class II · Moderate risk Ongoing

Refresh P.M.

Reason Lack of Assurance of Sterility: The impacted lots may contain a breach in the tube seal.

AbbVie Inc. D-0664-2024
Class II · Moderate risk Ongoing

First Aid Antiseptic Ointment

Reason Incorrect/Undeclared Excipients: The inactive ingredients labeled on the product boxes and tubes are listed as "mineral oil , petrolatum ". The inactive ingredients in the actual product are polyethylene glycol 400 , polyethylene glycol 4000.

Zhejiang Jingwei Pharmaceutical Co., Ltd. D-0013-2025
Class II · Moderate risk Ongoing

TIRZEPATIDE 60 mg/3mL

Reason Lack of Assurance of Sterility

ProRx LLC NDC 84139-210-02 D-0656-2024
Class II · Moderate risk Ongoing

TIRZEPATIDE 20 mg/2mL

Reason Lack of Assurance of Sterility

ProRx LLC NDC 84139-210-01 D-0655-2024